Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
6.12
Dollar change
+0.27
Percentage change
4.62
%
IndexRUT P/E- EPS (ttm)-0.31 Insider Own64.21% Shs Outstand306.56M Perf Week0.66%
Market Cap1.89B Forward P/E9.32 EPS next Y0.66 Insider Trans0.00% Shs Float110.43M Perf Month7.18%
Income-83.99M PEG- EPS next Q0.09 Inst Own24.62% Short Float1.87% Perf Quarter4.26%
Sales2.39B P/S0.79 EPS this Y-8.93% Inst Trans-0.44% Short Ratio1.39 Perf Half Y42.66%
Book/sh0.06 P/B94.85 EPS next Y12.69% ROA-2.31% Short Interest2.07M Perf Year374.42%
Cash/sh0.32 P/C19.05 EPS next 5Y-1.50% ROE-52.79% 52W Range1.24 - 6.46 Perf YTD0.82%
Dividend Est.- P/FCF13.85 EPS past 5Y-23.74% ROI-3.30% 52W High-5.26% Beta1.33
Dividend TTM- Quick Ratio0.94 Sales past 5Y7.85% Gross Margin35.79% 52W Low393.55% ATR (14)0.29
Dividend Ex-Date- Current Ratio1.63 EPS Y/Y TTM63.98% Oper. Margin10.99% RSI (14)59.61 Volatility4.22% 5.23%
Employees7850 Debt/Eq139.06 Sales Y/Y TTM8.20% Profit Margin-3.51% Recom2.00 Target Price7.31
Option/ShortYes / Yes LT Debt/Eq127.55 EPS Q/Q-1315.38% Payout- Rel Volume1.29 Prev Close5.85
Sales Surprise-2.83% EPS Surprise55.21% Sales Q/Q1.18% EarningsMar 01 BMO Avg Volume1.48M Price6.12
SMA208.62% SMA509.25% SMA20037.66% Trades Volume1,913,485 Change4.62%
Date Action Analyst Rating Change Price Target Change
Apr-07-21Resumed RBC Capital Mkts Sector Perform $5
Mar-08-21Upgrade Goldman Sell → Buy $4 → $6.50
Dec-14-20Upgrade Guggenheim Neutral → Buy $5.50
Dec-14-20Upgrade Barclays Equal Weight → Overweight $4.50 → $6
Jul-27-20Initiated Goldman Sell $4
May-12-20Upgrade Guggenheim Sell → Neutral
Dec-12-19Downgrade Raymond James Outperform → Mkt Perform
Nov-12-19Downgrade JP Morgan Neutral → Underweight
Nov-07-19Downgrade SVB Leerink Outperform → Mkt Perform
Jul-22-19Upgrade SVB Leerink Mkt Perform → Outperform $11 → $5
Mar-25-24 04:05PM
Mar-20-24 06:11AM
Mar-04-24 09:07AM
Mar-01-24 09:30AM
07:15AM
06:32AM Loading…
06:32AM
06:00AM
Feb-27-24 08:00AM
Feb-13-24 08:00AM
Feb-08-24 04:05PM
Jan-31-24 04:05PM
Jan-25-24 07:30AM
Jan-10-24 08:00AM
Jan-04-24 04:05PM
Dec-22-23 10:54AM
08:00AM Loading…
Dec-21-23 08:00AM
Dec-15-23 04:05PM
Dec-07-23 08:00AM
Dec-01-23 08:00AM
Nov-08-23 05:57PM
Nov-07-23 09:30AM
07:04AM
06:22AM
06:00AM
Nov-03-23 12:40PM
08:00AM
Nov-01-23 10:01AM
07:15AM
Oct-31-23 10:01AM
09:55AM
12:00PM Loading…
Oct-25-23 12:00PM
09:40AM
Oct-23-23 04:05PM
Oct-17-23 12:10PM
Oct-12-23 08:00AM
Oct-06-23 08:50AM
Oct-05-23 08:00AM
Oct-04-23 09:40AM
Sep-06-23 04:00PM
08:01AM
08:00AM
Aug-29-23 04:01PM
Aug-25-23 08:00AM
Aug-24-23 04:01PM
Aug-07-23 10:39AM
Aug-05-23 01:03AM
Aug-04-23 09:30AM
07:25AM
06:13AM
06:00AM
Jul-26-23 08:00AM
Jul-21-23 12:10PM
Jul-06-23 10:36AM
08:00AM
Jul-05-23 01:23PM
09:27AM
Jul-03-23 02:32PM
02:08PM
02:01PM
02:00PM
Jun-15-23 08:00AM
Jun-14-23 08:00AM
May-29-23 10:37AM
May-24-23 08:00AM
May-16-23 08:00AM
May-07-23 01:18PM
May-05-23 11:35PM
06:10AM
06:00AM
May-01-23 10:01AM
Apr-28-23 10:00AM
Apr-17-23 08:00AM
06:30AM
04:01AM
Apr-12-23 08:00AM
Apr-03-23 10:39AM
Mar-06-23 09:48AM
Mar-03-23 02:04AM
Mar-02-23 07:25AM
06:01AM
06:00AM
Jan-31-23 08:00AM
Jan-25-23 04:06PM
Jan-12-23 05:04PM
Jan-04-23 09:00AM
Dec-20-22 09:03AM
08:00AM
Nov-23-22 08:00AM
Nov-22-22 04:05PM
Nov-14-22 02:05PM
Nov-11-22 08:00AM
Nov-09-22 06:05AM
Nov-04-22 07:25AM
06:00AM
Nov-03-22 08:15PM
Nov-02-22 08:00AM
Oct-31-22 04:05PM
Oct-25-22 09:08AM
Oct-18-22 08:38AM
Oct-06-22 08:00AM
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOYER ANDREW SExecutive Vice PresidentAug 11 '23Sale4.1329,302120,921244,739Aug 15 04:30 PM